Global Kidney Cancer Drugs Market Report, History and Forecast 2018-2029, Breakdown Data by Manufacturers, Key Regions, Types and Application

• Description
• Table of Contents
• Table of Figures
• PDF Download

• Description
• Table of Contents
• Table of Figures
• PDF Download

Kidney cancer, also known as renal cancer, is a type of cancer that starts in the cells in the kidney. The two most common types of kidney cancer are renal cell carcinoma (RCC) and transitional cell carcinoma (TCC) of the renal pelvis. These names reflect the type of cell from which the cancer developed. The different types of kidney cancer (such as RCC and TCC) develop in different ways, meaning that the diseases have different long term outcomes, and need to be staged and treated in different ways. RCC is responsible for approximately 80% of primary renal cancers, and TCC accounts the majority of the remainder.

Kidney Cancer Drugs report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Kidney Cancer Drugs market is projected to reach US$ 5501.9 million in 2029, increasing from US$ 3970.1 million in 2022, with the CAGR of 4.3% during the period of 2023 to 2029. Demand from Renal Cell Carcinoma (RCC) and Transitional Cell Carcinoma (TCC) are the major drivers for the industry.

Biological therapies are drugs which are used to kill cancer cells or stop them from growing. Biological therapies are used to try to shrink or control advanced kidney cancer and help people to live longer. You may be given biological therapies for kidney cancer that has already spread, or is at high-risk of coming back after surgery.

Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Kidney Cancer Drugs market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.

Manufacturers, Type, Application and Regions Listed in the Report:
By Company
    Bayer
    Roche
    GlaxoSmithKline
    Novartis
    Pfizer
    Abbott Laboratories
    Active Biotech
    Amgen
    Argos Therapeutics
    ArQule
    AVEO Pharmaceuticals
    Bionomics
    Bristol-Myers Squibb
    Cerulean Pharma
    Exelixis
    Genentech
    immatics biotechnologies
    Immunicum
    Ono Pharmaceutical
    Onyx Therapeutics
    Oxford BioMedica
    Prometheus Laboratories
    Seattle Genetics
    Taiwan Liposome
    Tracon Pharmaceuticals
    Wilex

Segment by Type
    Angiogenesis Inhibitors
    mTOR Inhibitors
    Monoclonal Antibodies
    Cytokine Immunotherapy (IL-2)

Segment by Application
    Renal Cell Carcinoma (RCC)
    Transitional Cell Carcinoma (TCC)

Segment by Region
    North America
        U.S.
        Canada
    Europe
        Germany
        France
        U.K.
        Italy
        Russia
    Asia-Pacific
        China
        Japan
        South Korea
        India
        Australia
        Taiwan
        Indonesia
        Thailand
        Malaysia
        Philippines
        Vietnam
    Latin America
        Mexico
        Brazil
        Argentina
    Middle East & Africa
        Turkey
        Saudi Arabia
        U.A.E

Each chapter of the report provides detailed information for readers to understand the Kidney Cancer Drugs market further:
Chapter 1: Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2023.
Chapter 2: Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Kidney Cancer Drugs, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Kidney Cancer Drugs industry.
Chapter 3: Historical (2018-2022) and forecast (2023-2029) volume and revenue analysis of Kidney Cancer Drugs in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4: Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2023.
Chapter 5 to 9: Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10: Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Kidney Cancer Drugs introduction, etc. Kidney Cancer Drugs Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11: Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12: Market Channel, Distributors and Customers are listed.
Chapter 13: QYResearch’s Conclusions of Kidney Cancer Drugs market based on comprehensive survey.
Chapter 14: Methodology and Data Sources adopted by QYResearch.

 1 Kidney Cancer Drugs Market Overview
    1.1 Kidney Cancer Drugs Product Overview
    1.2 Kidney Cancer Drugs Market Segment by Type
        1.2.1 Angiogenesis Inhibitors
        1.2.2 mTOR Inhibitors
        1.2.3 Monoclonal Antibodies
        1.2.4 Cytokine Immunotherapy (IL-2)
    1.3 Global Kidney Cancer Drugs Market Size by Type
        1.3.1 Global Kidney Cancer Drugs Market Size Overview by Type (2018-2029)
        1.3.2 Global Kidney Cancer Drugs Historic Market Size Review by Type (2018-2023)
        1.3.3 Global Kidney Cancer Drugs Forecasted Market Size by Type (2024-2029)
    1.4 Key Regions Market Size Segment by Type
        1.4.1 North America Kidney Cancer Drugs Sales Breakdown by Type (2018-2023)
        1.4.2 Europe Kidney Cancer Drugs Sales Breakdown by Type (2018-2023)
        1.4.3 Asia-Pacific Kidney Cancer Drugs Sales Breakdown by Type (2018-2023)
        1.4.4 Latin America Kidney Cancer Drugs Sales Breakdown by Type (2018-2023)
        1.4.5 Middle East and Africa Kidney Cancer Drugs Sales Breakdown by Type (2018-2023)

 2 Global Kidney Cancer Drugs Market Competition by Company
    2.1 Global Top Players by Kidney Cancer Drugs Sales (2018-2023)
    2.2 Global Top Players by Kidney Cancer Drugs Revenue (2018-2023)
    2.3 Global Top Players by Kidney Cancer Drugs Price (2018-2023)
    2.4 Global Top Manufacturers Kidney Cancer Drugs Manufacturing Base Distribution, Sales Area, Product Type
    2.5 Kidney Cancer Drugs Market Competitive Situation and Trends
        2.5.1 Kidney Cancer Drugs Market Concentration Rate (2018-2023)
        2.5.2 Global 5 and 10 Largest Manufacturers by Kidney Cancer Drugs Sales and Revenue in 2022
    2.6 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Kidney Cancer Drugs as of 2022)
    2.7 Date of Key Manufacturers Enter into Kidney Cancer Drugs Market
    2.8 Key Manufacturers Kidney Cancer Drugs Product Offered
    2.9 Mergers & Acquisitions, Expansion

 3 Kidney Cancer Drugs Status and Outlook by Region
    3.1 Global Kidney Cancer Drugs Market Size and CAGR by Region: 2018 VS 2022 VS 2029
    3.2 Global Kidney Cancer Drugs Historic Market Size by Region
        3.2.1 Global Kidney Cancer Drugs Sales in Volume by Region (2018-2023)
        3.2.2 Global Kidney Cancer Drugs Sales in Value by Region (2018-2023)
        3.2.3 Global Kidney Cancer Drugs Sales (Volume & Value) Price and Gross Margin (2018-2023)
    3.3 Global Kidney Cancer Drugs Forecasted Market Size by Region
        3.3.1 Global Kidney Cancer Drugs Sales in Volume by Region (2024-2029)
        3.3.2 Global Kidney Cancer Drugs Sales in Value by Region (2024-2029)
        3.3.3 Global Kidney Cancer Drugs Sales (Volume & Value), Price and Gross Margin (2024-2029)

 4 Global Kidney Cancer Drugs by Application
    4.1 Kidney Cancer Drugs Market Segment by Application
        4.1.1 Renal Cell Carcinoma (RCC)
        4.1.2 Transitional Cell Carcinoma (TCC)
    4.2 Global Kidney Cancer Drugs Market Size by Application
        4.2.1 Global Kidney Cancer Drugs Market Size Overview by Application (2018-2029)
        4.2.2 Global Kidney Cancer Drugs Historic Market Size Review by Application (2018-2023)
        4.2.3 Global Kidney Cancer Drugs Forecasted Market Size by Application (2024-2029)
    4.3 Key Regions Market Size Segment by Application
        4.3.1 North America Kidney Cancer Drugs Sales Breakdown by Application (2018-2023)
        4.3.2 Europe Kidney Cancer Drugs Sales Breakdown by Application (2018-2023)
        4.3.3 Asia-Pacific Kidney Cancer Drugs Sales Breakdown by Application (2018-2023)
        4.3.4 Latin America Kidney Cancer Drugs Sales Breakdown by Application (2018-2023)
        4.3.5 Middle East and Africa Kidney Cancer Drugs Sales Breakdown by Application (2018-2023)

 5 North America Kidney Cancer Drugs by Country
    5.1 North America Kidney Cancer Drugs Historic Market Size by Country
        5.1.1 North America Kidney Cancer Drugs Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
        5.1.2 North America Kidney Cancer Drugs Sales in Volume by Country (2018-2023)
        5.1.3 North America Kidney Cancer Drugs Sales in Value by Country (2018-2023)
    5.2 North America Kidney Cancer Drugs Forecasted Market Size by Country
        5.2.1 North America Kidney Cancer Drugs Sales in Volume by Country (2024-2029)
        5.2.2 North America Kidney Cancer Drugs Sales in Value by Country (2024-2029)

 6 Europe Kidney Cancer Drugs by Country
    6.1 Europe Kidney Cancer Drugs Historic Market Size by Country
        6.1.1 Europe Kidney Cancer Drugs Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
        6.1.2 Europe Kidney Cancer Drugs Sales in Volume by Country (2018-2023)
        6.1.3 Europe Kidney Cancer Drugs Sales in Value by Country (2018-2023)
    6.2 Europe Kidney Cancer Drugs Forecasted Market Size by Country
        6.2.1 Europe Kidney Cancer Drugs Sales in Volume by Country (2024-2029)
        6.2.2 Europe Kidney Cancer Drugs Sales in Value by Country (2024-2029)

 7 Asia-Pacific Kidney Cancer Drugs by Region
    7.1 Asia-Pacific Kidney Cancer Drugs Historic Market Size by Region
        7.1.1 Asia-Pacific Kidney Cancer Drugs Market Size Growth Rate (CAGR) by Region: 2018 VS 2022 VS 2029
        7.1.2 Asia-Pacific Kidney Cancer Drugs Sales in Volume by Region (2018-2023)
        7.1.3 Asia-Pacific Kidney Cancer Drugs Sales in Value by Region (2018-2023)
    7.2 Asia-Pacific Kidney Cancer Drugs Forecasted Market Size by Region
        7.2.1 Asia-Pacific Kidney Cancer Drugs Sales in Volume by Region (2024-2029)
        7.2.2 Asia-Pacific Kidney Cancer Drugs Sales in Value by Region (2024-2029)

 8 Latin America Kidney Cancer Drugs by Country
    8.1 Latin America Kidney Cancer Drugs Historic Market Size by Country
        8.1.1 Latin America Kidney Cancer Drugs Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
        8.1.2 Latin America Kidney Cancer Drugs Sales in Volume by Country (2018-2023)
        8.1.3 Latin America Kidney Cancer Drugs Sales in Value by Country (2018-2023)
    8.2 Latin America Kidney Cancer Drugs Forecasted Market Size by Country
        8.2.1 Latin America Kidney Cancer Drugs Sales in Volume by Country (2024-2029)
        8.2.2 Latin America Kidney Cancer Drugs Sales in Value by Country (2024-2029)

 9 Middle East and Africa Kidney Cancer Drugs by Country
    9.1 Middle East and Africa Kidney Cancer Drugs Historic Market Size by Country
        9.1.1 Middle East and Africa Kidney Cancer Drugs Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
        9.1.2 Middle East and Africa Kidney Cancer Drugs Sales in Volume by Country (2018-2023)
        9.1.3 Middle East and Africa Kidney Cancer Drugs Sales in Value by Country (2018-2023)
    9.2 Middle East and Africa Kidney Cancer Drugs Forecasted Market Size by Country
        9.2.1 Middle East and Africa Kidney Cancer Drugs Sales in Volume by Country (2024-2029)
        9.2.2 Middle East and Africa Kidney Cancer Drugs Sales in Value by Country (2024-2029)

 10 Company Profiles
    10.1 Bayer
        10.1.1 Bayer Company Information
        10.1.2 Bayer Introduction and Business Overview
        10.1.3 Bayer Kidney Cancer Drugs Sales, Revenue and Gross Margin (2018-2023)
        10.1.4 Bayer Kidney Cancer Drugs Products Offered
        10.1.5 Bayer Recent Development
    10.2 Roche
        10.2.1 Roche Company Information
        10.2.2 Roche Introduction and Business Overview
        10.2.3 Roche Kidney Cancer Drugs Sales, Revenue and Gross Margin (2018-2023)
        10.2.4 Roche Kidney Cancer Drugs Products Offered
        10.2.5 Roche Recent Development
    10.3 GlaxoSmithKline
        10.3.1 GlaxoSmithKline Company Information
        10.3.2 GlaxoSmithKline Introduction and Business Overview
        10.3.3 GlaxoSmithKline Kidney Cancer Drugs Sales, Revenue and Gross Margin (2018-2023)
        10.3.4 GlaxoSmithKline Kidney Cancer Drugs Products Offered
        10.3.5 GlaxoSmithKline Recent Development
    10.4 Novartis
        10.4.1 Novartis Company Information
        10.4.2 Novartis Introduction and Business Overview
        10.4.3 Novartis Kidney Cancer Drugs Sales, Revenue and Gross Margin (2018-2023)
        10.4.4 Novartis Kidney Cancer Drugs Products Offered
        10.4.5 Novartis Recent Development
    10.5 Pfizer
        10.5.1 Pfizer Company Information
        10.5.2 Pfizer Introduction and Business Overview
        10.5.3 Pfizer Kidney Cancer Drugs Sales, Revenue and Gross Margin (2018-2023)
        10.5.4 Pfizer Kidney Cancer Drugs Products Offered
        10.5.5 Pfizer Recent Development
    10.6 Abbott Laboratories
        10.6.1 Abbott Laboratories Company Information
        10.6.2 Abbott Laboratories Introduction and Business Overview
        10.6.3 Abbott Laboratories Kidney Cancer Drugs Sales, Revenue and Gross Margin (2018-2023)
        10.6.4 Abbott Laboratories Kidney Cancer Drugs Products Offered
        10.6.5 Abbott Laboratories Recent Development
    10.7 Active Biotech
        10.7.1 Active Biotech Company Information
        10.7.2 Active Biotech Introduction and Business Overview
        10.7.3 Active Biotech Kidney Cancer Drugs Sales, Revenue and Gross Margin (2018-2023)
        10.7.4 Active Biotech Kidney Cancer Drugs Products Offered
        10.7.5 Active Biotech Recent Development
    10.8 Amgen
        10.8.1 Amgen Company Information
        10.8.2 Amgen Introduction and Business Overview
        10.8.3 Amgen Kidney Cancer Drugs Sales, Revenue and Gross Margin (2018-2023)
        10.8.4 Amgen Kidney Cancer Drugs Products Offered
        10.8.5 Amgen Recent Development
    10.9 Argos Therapeutics
        10.9.1 Argos Therapeutics Company Information
        10.9.2 Argos Therapeutics Introduction and Business Overview
        10.9.3 Argos Therapeutics Kidney Cancer Drugs Sales, Revenue and Gross Margin (2018-2023)
        10.9.4 Argos Therapeutics Kidney Cancer Drugs Products Offered
        10.9.5 Argos Therapeutics Recent Development
    10.10 ArQule
        10.10.1 ArQule Company Information
        10.10.2 ArQule Introduction and Business Overview
        10.10.3 ArQule Kidney Cancer Drugs Sales, Revenue and Gross Margin (2018-2023)
        10.10.4 ArQule Kidney Cancer Drugs Products Offered
        10.10.5 ArQule Recent Development
    10.11 AVEO Pharmaceuticals
        10.11.1 AVEO Pharmaceuticals Company Information
        10.11.2 AVEO Pharmaceuticals Introduction and Business Overview
        10.11.3 AVEO Pharmaceuticals Kidney Cancer Drugs Sales, Revenue and Gross Margin (2018-2023)
        10.11.4 AVEO Pharmaceuticals Kidney Cancer Drugs Products Offered
        10.11.5 AVEO Pharmaceuticals Recent Development
    10.12 Bionomics
        10.12.1 Bionomics Company Information
        10.12.2 Bionomics Introduction and Business Overview
        10.12.3 Bionomics Kidney Cancer Drugs Sales, Revenue and Gross Margin (2018-2023)
        10.12.4 Bionomics Kidney Cancer Drugs Products Offered
        10.12.5 Bionomics Recent Development
    10.13 Bristol-Myers Squibb
        10.13.1 Bristol-Myers Squibb Company Information
        10.13.2 Bristol-Myers Squibb Introduction and Business Overview
        10.13.3 Bristol-Myers Squibb Kidney Cancer Drugs Sales, Revenue and Gross Margin (2018-2023)
        10.13.4 Bristol-Myers Squibb Kidney Cancer Drugs Products Offered
        10.13.5 Bristol-Myers Squibb Recent Development
    10.14 Cerulean Pharma
        10.14.1 Cerulean Pharma Company Information
        10.14.2 Cerulean Pharma Introduction and Business Overview
        10.14.3 Cerulean Pharma Kidney Cancer Drugs Sales, Revenue and Gross Margin (2018-2023)
        10.14.4 Cerulean Pharma Kidney Cancer Drugs Products Offered
        10.14.5 Cerulean Pharma Recent Development
    10.15 Exelixis
        10.15.1 Exelixis Company Information
        10.15.2 Exelixis Introduction and Business Overview
        10.15.3 Exelixis Kidney Cancer Drugs Sales, Revenue and Gross Margin (2018-2023)
        10.15.4 Exelixis Kidney Cancer Drugs Products Offered
        10.15.5 Exelixis Recent Development
    10.16 Genentech
        10.16.1 Genentech Company Information
        10.16.2 Genentech Introduction and Business Overview
        10.16.3 Genentech Kidney Cancer Drugs Sales, Revenue and Gross Margin (2018-2023)
        10.16.4 Genentech Kidney Cancer Drugs Products Offered
        10.16.5 Genentech Recent Development
    10.17 immatics biotechnologies
        10.17.1 immatics biotechnologies Company Information
        10.17.2 immatics biotechnologies Introduction and Business Overview
        10.17.3 immatics biotechnologies Kidney Cancer Drugs Sales, Revenue and Gross Margin (2018-2023)
        10.17.4 immatics biotechnologies Kidney Cancer Drugs Products Offered
        10.17.5 immatics biotechnologies Recent Development
    10.18 Immunicum
        10.18.1 Immunicum Company Information
        10.18.2 Immunicum Introduction and Business Overview
        10.18.3 Immunicum Kidney Cancer Drugs Sales, Revenue and Gross Margin (2018-2023)
        10.18.4 Immunicum Kidney Cancer Drugs Products Offered
        10.18.5 Immunicum Recent Development
    10.19 Ono Pharmaceutical
        10.19.1 Ono Pharmaceutical Company Information
        10.19.2 Ono Pharmaceutical Introduction and Business Overview
        10.19.3 Ono Pharmaceutical Kidney Cancer Drugs Sales, Revenue and Gross Margin (2018-2023)
        10.19.4 Ono Pharmaceutical Kidney Cancer Drugs Products Offered
        10.19.5 Ono Pharmaceutical Recent Development
    10.20 Onyx Therapeutics
        10.20.1 Onyx Therapeutics Company Information
        10.20.2 Onyx Therapeutics Introduction and Business Overview
        10.20.3 Onyx Therapeutics Kidney Cancer Drugs Sales, Revenue and Gross Margin (2018-2023)
        10.20.4 Onyx Therapeutics Kidney Cancer Drugs Products Offered
        10.20.5 Onyx Therapeutics Recent Development
    10.21 Oxford BioMedica
        10.21.1 Oxford BioMedica Company Information
        10.21.2 Oxford BioMedica Introduction and Business Overview
        10.21.3 Oxford BioMedica Kidney Cancer Drugs Sales, Revenue and Gross Margin (2018-2023)
        10.21.4 Oxford BioMedica Kidney Cancer Drugs Products Offered
        10.21.5 Oxford BioMedica Recent Development
    10.22 Prometheus Laboratories
        10.22.1 Prometheus Laboratories Company Information
        10.22.2 Prometheus Laboratories Introduction and Business Overview
        10.22.3 Prometheus Laboratories Kidney Cancer Drugs Sales, Revenue and Gross Margin (2018-2023)
        10.22.4 Prometheus Laboratories Kidney Cancer Drugs Products Offered
        10.22.5 Prometheus Laboratories Recent Development
    10.23 Seattle Genetics
        10.23.1 Seattle Genetics Company Information
        10.23.2 Seattle Genetics Introduction and Business Overview
        10.23.3 Seattle Genetics Kidney Cancer Drugs Sales, Revenue and Gross Margin (2018-2023)
        10.23.4 Seattle Genetics Kidney Cancer Drugs Products Offered
        10.23.5 Seattle Genetics Recent Development
    10.24 Taiwan Liposome
        10.24.1 Taiwan Liposome Company Information
        10.24.2 Taiwan Liposome Introduction and Business Overview
        10.24.3 Taiwan Liposome Kidney Cancer Drugs Sales, Revenue and Gross Margin (2018-2023)
        10.24.4 Taiwan Liposome Kidney Cancer Drugs Products Offered
        10.24.5 Taiwan Liposome Recent Development
    10.25 Tracon Pharmaceuticals
        10.25.1 Tracon Pharmaceuticals Company Information
        10.25.2 Tracon Pharmaceuticals Introduction and Business Overview
        10.25.3 Tracon Pharmaceuticals Kidney Cancer Drugs Sales, Revenue and Gross Margin (2018-2023)
        10.25.4 Tracon Pharmaceuticals Kidney Cancer Drugs Products Offered
        10.25.5 Tracon Pharmaceuticals Recent Development
    10.26 Wilex
        10.26.1 Wilex Company Information
        10.26.2 Wilex Introduction and Business Overview
        10.26.3 Wilex Kidney Cancer Drugs Sales, Revenue and Gross Margin (2018-2023)
        10.26.4 Wilex Kidney Cancer Drugs Products Offered
        10.26.5 Wilex Recent Development

 11 Upstream, Opportunities, Challenges, Risks and Influences Factors Analysis
    11.1 Kidney Cancer Drugs Key Raw Materials
        11.1.1 Key Raw Materials
        11.1.2 Key Raw Materials Price
        11.1.3 Raw Materials Key Suppliers
    11.2 Manufacturing Cost Structure
        11.2.1 Raw Materials
        11.2.2 Labor Cost
        11.2.3 Manufacturing Expenses
    11.3 Kidney Cancer Drugs Industrial Chain Analysis
    11.4 Kidney Cancer Drugs Market Dynamics
        11.4.1 Kidney Cancer Drugs Industry Trends
        11.4.2 Kidney Cancer Drugs Market Drivers
        11.4.3 Kidney Cancer Drugs Market Challenges
        11.4.4 Kidney Cancer Drugs Market Restraints

 12 Market Strategy Analysis, Distributors
    12.1 Sales Channel
    12.2 Kidney Cancer Drugs Distributors
    12.3 Kidney Cancer Drugs Downstream Customers

 13 Research Findings and Conclusion

 14 Appendix
    14.1 Research Methodology
        14.1.1 Methodology/Research Approach
        14.1.2 Data Source
    14.2 Author Details
    14.3 Disclaimer

List of Tables
    Table 1. Major Company of Angiogenesis Inhibitors
    Table 2. Major Company of mTOR Inhibitors
    Table 3. Major Company of Monoclonal Antibodies
    Table 4. Major Company of Cytokine Immunotherapy (IL-2)
    Table 5. Global Kidney Cancer Drugs Sales by Type 2018 VS 2022 VS 2029 (US$ Million)
    Table 6. Global Kidney Cancer Drugs Sales by Type (2018-2023) & (K Units)
    Table 7. Global Kidney Cancer Drugs Sales Market Share in Volume by Type (2018-2023)
    Table 8. Global Kidney Cancer Drugs Sales by Type (2018-2023) & (US& Million)
    Table 9. Global Kidney Cancer Drugs Market Share in Value by Type (2018-2023)
    Table 10. Global Kidney Cancer Drugs Price by Type (2018-2023) & (USD/Unit)
    Table 11. Global Kidney Cancer Drugs Sales by Type (2024-2029) & (K Units)
    Table 12. Global Kidney Cancer Drugs Sales Market Share in Volume by Type (2024-2029)
    Table 13. Global Kidney Cancer Drugs Sales by Type (2024-2029) & (US$ Million)
    Table 14. Global Kidney Cancer Drugs Sales Market Share in Value by Type (2024-2029)
    Table 15. Global Kidney Cancer Drugs Price by Type (2024-2029) & (USD/Unit)
    Table 16. North America Kidney Cancer Drugs Sales by Type (2018-2023) & (K Units)
    Table 17. North America Kidney Cancer Drugs Sales by Type (2018-2023) & (US$ Million)
    Table 18. Europe Kidney Cancer Drugs Sales (K Units) by Type (2018-2023)
    Table 19. Europe Kidney Cancer Drugs Sales by Type (2018-2023) & (US$ Million)
    Table 20. Asia-Pacific Kidney Cancer Drugs Sales (K Units) by Type (2018-2023)
    Table 21. Asia-Pacific Kidney Cancer Drugs Sales by Type (2018-2023) & (US$ Million)
    Table 22. Latin America Kidney Cancer Drugs Sales (K Units) by Type (2018-2023)
    Table 23. Latin America Kidney Cancer Drugs Sales by Type (2018-2023) & (US$ Million)
    Table 24. Middle East and Africa Kidney Cancer Drugs Sales (K Units) by Type (2018-2023)
    Table 25. Middle East and Africa Kidney Cancer Drugs Sales by Type (2018-2023) & (US$ Million)
    Table 26. Global Kidney Cancer Drugs Sales by Company (2018-2023) & (K Units)
    Table 27. Global Kidney Cancer Drugs Sales Share by Company (2018-2023)
    Table 28. Global Kidney Cancer Drugs Revenue by Company (2018-2023) & (US$ Million)
    Table 29. Global Kidney Cancer Drugs Revenue Share by Company (2018-2023)
    Table 30. Global Market Kidney Cancer Drugs Price by Company (2018-2023) & (USD/Unit)
    Table 31. Global Kidney Cancer Drugs Top Manufacturers Manufacturing Base Distribution and Sales Area
    Table 32. Global Kidney Cancer Drugs Manufacturers Market Concentration Ratio (CR5 and HHI)
    Table 33. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Kidney Cancer Drugs as of 2022)
    Table 34. Date of Key Manufacturers Enter into Kidney Cancer Drugs Market
    Table 35. Key Manufacturers Kidney Cancer Drugs Product Type
    Table 36. Mergers & Acquisitions, Expansion Plans
    Table 37. Global Kidney Cancer Drugs Market Size Comparison by Region (US$ Million): 2018 VS 2022 VS 2029
    Table 38. Global Kidney Cancer Drugs Sales by Region (2018-2023) & (K Units)
    Table 39. Global Kidney Cancer Drugs Sales Market Share in Volume by Region (2018-2023)
    Table 40. Global Kidney Cancer Drugs Sales by Region (2018-2023) & (US$ Million)
    Table 41. Global Kidney Cancer Drugs Sales Market Share in Value by Region (2018-2023)
    Table 42. Global Kidney Cancer Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
    Table 43. Global Kidney Cancer Drugs Sales by Region (2024-2029) & (K Units)
    Table 44. Global Kidney Cancer Drugs Sales Market Share in Volume by Region (2024-2029)
    Table 45. Global Kidney Cancer Drugs Sales by Region (2024-2029) & (US$ Million)
    Table 46. Global Kidney Cancer Drugs Sales Market Share in Value by Region (2024-2029)
    Table 47. Global Kidney Cancer Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2024-2029)
    Table 48. Global Kidney Cancer Drugs Sales by Application: 2018 VS 2022 VS 2029 (US$ Million)
    Table 49. Global Kidney Cancer Drugs Sales by Application (2018-2023) & (K Units)
    Table 50. Global Kidney Cancer Drugs Sales Market Share in Volume by Application (2018-2023)
    Table 51. Global Kidney Cancer Drugs Sales by Application (2018-2023) & (US$ Million)
    Table 52. Global Kidney Cancer Drugs Sales Market Share in Value by Application (2018-2023)
    Table 53. Global Kidney Cancer Drugs Price by Application (2018-2023) & (USD/Unit)
    Table 54. Global Kidney Cancer Drugs Sales by Application (2024-2029) & (K Units)
    Table 55. Global Kidney Cancer Drugs Sales Market Share in Volume by Application (2024-2029)
    Table 56. Global Kidney Cancer Drugs Sales by Application (2024-2029) & (US$ Million)
    Table 57. Global Kidney Cancer Drugs Sales Market Share in Value by Application (2024-2029)
    Table 58. Global Kidney Cancer Drugs Price by Application (2024-2029) & (USD/Unit)
    Table 59. North America Kidney Cancer Drugs Sales by Application (2018-2023) (K Units) 
    Table 60. North America Kidney Cancer Drugs Sales by Application (2018-2023) & (US$ Million)
    Table 61. Europe Kidney Cancer Drugs Sales by Application (2018-2023) (K Units) 
    Table 62. Europe Kidney Cancer Drugs Sales by Application (2018-2023) & (US$ Million)
    Table 63. Asia-Pacific Kidney Cancer Drugs Sales by Application (2018-2023) (K Units) 
    Table 64. Asia-Pacific Kidney Cancer Drugs Sales by Application (2018-2023) & (US$ Million)
    Table 65. Latin America Kidney Cancer Drugs Sales by Application (2018-2023) (K Units) 
    Table 66. Latin America Kidney Cancer Drugs Sales by Application (2018-2023) & (US$ Million)
    Table 67. Middle East and Africa Kidney Cancer Drugs Sales by Application (2018-2023) (K Units) 
    Table 68. Middle East and Africa Kidney Cancer Drugs Sales by Application (2018-2023) & (US$ Million)
    Table 69. North America Kidney Cancer Drugs Sales by Country (2018-2023) & (K Units)
    Table 70. North America Kidney Cancer Drugs Sales Market Share in Volume by Country (2018-2023)
    Table 71. North America Kidney Cancer Drugs Sales by Country (2018-2023) & (US$ Million)
    Table 72. North America Kidney Cancer Drugs Sales Market Share in Value by Country (2018-2023)
    Table 73. North America Kidney Cancer Drugs Sales by Country (2024-2029) & (K Units)
    Table 74. North America Kidney Cancer Drugs Sales Market Share in Volume by Country (2024-2029)
    Table 75. North America Kidney Cancer Drugs Sales by Country (2024-2029) & (US$ Million)
    Table 76. North America Kidney Cancer Drugs Sales Market Share in Value by Country (2024-2029)
    Table 77. Europe Kidney Cancer Drugs Sales by Country (2018-2023) & (K Units)
    Table 78. Europe Kidney Cancer Drugs Sales Market Share in Volume by Country (2018-2023)
    Table 79. Europe Kidney Cancer Drugs Sales by Country (2018-2023) & (US$ Million)
    Table 80. Europe Kidney Cancer Drugs Sales Market Share in Value by Country (2018-2023)
    Table 81. Europe Kidney Cancer Drugs Sales by Country (2024-2029) & (K Units)
    Table 82. Europe Kidney Cancer Drugs Sales Market Share in Volume by Country (2024-2029)
    Table 83. Europe Kidney Cancer Drugs Sales by Country (2024-2029) & (US$ Million)
    Table 84. Europe Kidney Cancer Drugs Sales Market Share in Value by Country (2024-2029)
    Table 85. Asia-Pacific Kidney Cancer Drugs Sales by Region (2018-2023) & (K Units)
    Table 86. Asia-Pacific Kidney Cancer Drugs Sales Market Share in Volume by Region (2018-2023)
    Table 87. Asia-Pacific Kidney Cancer Drugs Sales by Region (2018-2023) & (US$ Million)
    Table 88. Asia-Pacific Kidney Cancer Drugs Sales Market Share in Value by Region (2018-2023)
    Table 89. Asia-Pacific Kidney Cancer Drugs Sales by Region (2024-2029) & (K Units)
    Table 90. Asia-Pacific Kidney Cancer Drugs Sales Market Share in Volume by Region (2024-2029)
    Table 91. Asia-Pacific Kidney Cancer Drugs Sales by Region (2024-2029) & (US$ Million)
    Table 92. Asia-Pacific Kidney Cancer Drugs Sales Market Share in Value by Region (2024-2029)
    Table 93. Latin America Kidney Cancer Drugs Sales by Country (2018-2023) & (K Units)
    Table 94. Latin America Kidney Cancer Drugs Sales Market Share in Volume by Country (2018-2023)
    Table 95. Latin America Kidney Cancer Drugs Sales by Country (2018-2023) & (US$ Million)
    Table 96. Latin America Kidney Cancer Drugs Sales Market Share in Value by Country (2018-2023)
    Table 97. Latin America Kidney Cancer Drugs Sales by Country (2024-2029) & (K Units)
    Table 98. Latin America Kidney Cancer Drugs Sales Market Share in Volume by Country (2024-2029)
    Table 99. Latin America Kidney Cancer Drugs Sales by Country (2024-2029) & (US$ Million)
    Table 100. Latin America Kidney Cancer Drugs Sales Market Share in Value by Country (2024-2029)
    Table 101. Middle East and Africa Kidney Cancer Drugs Sales by Country (2018-2023) & (K Units)
    Table 102. Middle East and Africa Kidney Cancer Drugs Sales Market Share in Volume by Country (2018-2023)
    Table 103. Middle East and Africa Kidney Cancer Drugs Sales by Country (2018-2023) & (US$ Million)
    Table 104. Middle East and Africa Kidney Cancer Drugs Sales Market Share in Value by Country (2018-2023)
    Table 105. Middle East and Africa Kidney Cancer Drugs Sales by Country (2024-2029) & (K Units)
    Table 106. Middle East and Africa Kidney Cancer Drugs Sales Market Share in Volume by Country (2024-2029)
    Table 107. Middle East and Africa Kidney Cancer Drugs Sales by Country (2024-2029) & (US$ Million)
    Table 108. Middle East and Africa Kidney Cancer Drugs Sales Market Share in Value by Country (2024-2029)
    Table 109. Bayer Company Information
    Table 110. Bayer Introduction and Business Overview
    Table 111. Bayer Kidney Cancer Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2018-2023)
    Table 112. Bayer Kidney Cancer Drugs Product
    Table 113. Bayer Recent Development
    Table 114. Roche Company Information
    Table 115. Roche Introduction and Business Overview
    Table 116. Roche Kidney Cancer Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2018-2023)
    Table 117. Roche Kidney Cancer Drugs Product
    Table 118. Roche Recent Development
    Table 119. GlaxoSmithKline Company Information
    Table 120. GlaxoSmithKline Introduction and Business Overview
    Table 121. GlaxoSmithKline Kidney Cancer Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2018-2023)
    Table 122. GlaxoSmithKline Kidney Cancer Drugs Product
    Table 123. GlaxoSmithKline Recent Development
    Table 124. Novartis Company Information
    Table 125. Novartis Introduction and Business Overview
    Table 126. Novartis Kidney Cancer Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2018-2023)
    Table 127. Novartis Kidney Cancer Drugs Product
    Table 128. Novartis Recent Development
    Table 129. Pfizer Company Information
    Table 130. Pfizer Introduction and Business Overview
    Table 131. Pfizer Kidney Cancer Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2018-2023)
    Table 132. Pfizer Kidney Cancer Drugs Product
    Table 133. Pfizer Recent Development
    Table 134. Abbott Laboratories Company Information
    Table 135. Abbott Laboratories Introduction and Business Overview
    Table 136. Abbott Laboratories Kidney Cancer Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2018-2023)
    Table 137. Abbott Laboratories Kidney Cancer Drugs Product
    Table 138. Abbott Laboratories Recent Development
    Table 139. Active Biotech Company Information
    Table 140. Active Biotech Introduction and Business Overview
    Table 141. Active Biotech Kidney Cancer Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2018-2023)
    Table 142. Active Biotech Kidney Cancer Drugs Product
    Table 143. Active Biotech Recent Development
    Table 144. Amgen Company Information
    Table 145. Amgen Introduction and Business Overview
    Table 146. Amgen Kidney Cancer Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2018-2023)
    Table 147. Amgen Kidney Cancer Drugs Product
    Table 148. Amgen Recent Development
    Table 149. Argos Therapeutics Company Information
    Table 150. Argos Therapeutics Introduction and Business Overview
    Table 151. Argos Therapeutics Kidney Cancer Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2018-2023)
    Table 152. Argos Therapeutics Kidney Cancer Drugs Product
    Table 153. Argos Therapeutics Recent Development
    Table 154. ArQule Company Information
    Table 155. ArQule Introduction and Business Overview
    Table 156. ArQule Kidney Cancer Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2018-2023)
    Table 157. ArQule Kidney Cancer Drugs Product
    Table 158. ArQule Recent Development
    Table 159. AVEO Pharmaceuticals Company Information
    Table 160. AVEO Pharmaceuticals Introduction and Business Overview
    Table 161. AVEO Pharmaceuticals Kidney Cancer Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2018-2023)
    Table 162. AVEO Pharmaceuticals Kidney Cancer Drugs Product
    Table 163. AVEO Pharmaceuticals Recent Development
    Table 164. Bionomics Company Information
    Table 165. Bionomics Introduction and Business Overview
    Table 166. Bionomics Kidney Cancer Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2018-2023)
    Table 167. Bionomics Kidney Cancer Drugs Product
    Table 168. Bionomics Recent Development
    Table 169. Bristol-Myers Squibb Company Information
    Table 170. Bristol-Myers Squibb Introduction and Business Overview
    Table 171. Bristol-Myers Squibb Kidney Cancer Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2018-2023)
    Table 172. Bristol-Myers Squibb Kidney Cancer Drugs Product
    Table 173. Bristol-Myers Squibb Recent Development
    Table 174. Cerulean Pharma Company Information
    Table 175. Cerulean Pharma Introduction and Business Overview
    Table 176. Cerulean Pharma Kidney Cancer Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2018-2023)
    Table 177. Cerulean Pharma Kidney Cancer Drugs Product
    Table 178. Cerulean Pharma Recent Development
    Table 179. Exelixis Company Information
    Table 180. Exelixis Introduction and Business Overview
    Table 181. Exelixis Kidney Cancer Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2018-2023)
    Table 182. Exelixis Kidney Cancer Drugs Product
    Table 183. Exelixis Recent Development
    Table 184. Genentech Company Information
    Table 185. Genentech Introduction and Business Overview
    Table 186. Genentech Kidney Cancer Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2018-2023)
    Table 187. Genentech Kidney Cancer Drugs Product
    Table 188. Genentech Recent Development
    Table 189. immatics biotechnologies Company Information
    Table 190. immatics biotechnologies Introduction and Business Overview
    Table 191. immatics biotechnologies Kidney Cancer Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2018-2023)
    Table 192. immatics biotechnologies Kidney Cancer Drugs Product
    Table 193. immatics biotechnologies Recent Development
    Table 194. Immunicum Company Information
    Table 195. Immunicum Introduction and Business Overview
    Table 196. Immunicum Kidney Cancer Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2018-2023)
    Table 197. Immunicum Kidney Cancer Drugs Product
    Table 198. Immunicum Recent Development
    Table 199. Ono Pharmaceutical Company Information
    Table 200. Ono Pharmaceutical Introduction and Business Overview
    Table 201. Ono Pharmaceutical Kidney Cancer Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2018-2023)
    Table 202. Ono Pharmaceutical Kidney Cancer Drugs Product
    Table 203. Ono Pharmaceutical Recent Development
    Table 204. Onyx Therapeutics Company Information
    Table 205. Onyx Therapeutics Introduction and Business Overview
    Table 206. Onyx Therapeutics Kidney Cancer Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2018-2023)
    Table 207. Onyx Therapeutics Kidney Cancer Drugs Product
    Table 208. Onyx Therapeutics Recent Development
    Table 209. Oxford BioMedica Company Information
    Table 210. Oxford BioMedica Introduction and Business Overview
    Table 211. Oxford BioMedica Kidney Cancer Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2018-2023)
    Table 212. Oxford BioMedica Kidney Cancer Drugs Product
    Table 213. Oxford BioMedica Recent Development
    Table 214. Prometheus Laboratories Company Information
    Table 215. Prometheus Laboratories Introduction and Business Overview
    Table 216. Prometheus Laboratories Kidney Cancer Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2018-2023)
    Table 217. Prometheus Laboratories Kidney Cancer Drugs Product
    Table 218. Prometheus Laboratories Recent Development
    Table 219. Seattle Genetics Company Information
    Table 220. Seattle Genetics Introduction and Business Overview
    Table 221. Seattle Genetics Kidney Cancer Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2018-2023)
    Table 222. Seattle Genetics Kidney Cancer Drugs Product
    Table 223. Seattle Genetics Recent Development
    Table 224. Taiwan Liposome Company Information
    Table 225. Taiwan Liposome Introduction and Business Overview
    Table 226. Taiwan Liposome Kidney Cancer Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2018-2023)
    Table 227. Taiwan Liposome Kidney Cancer Drugs Product
    Table 228. Taiwan Liposome Recent Development
    Table 229. Tracon Pharmaceuticals Introduction and Business Overview
    Table 230. Tracon Pharmaceuticals Kidney Cancer Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2018-2023)
    Table 231. Tracon Pharmaceuticals Kidney Cancer Drugs Product
    Table 232. Tracon Pharmaceuticals Recent Development
    Table 233. Tracon Pharmaceuticals Company Information
    Table 234. Wilex Company Information
    Table 235. Wilex Introduction and Business Overview
    Table 236. Wilex Kidney Cancer Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2018-2023)
    Table 237. Wilex Kidney Cancer Drugs Product
    Table 238. Wilex Recent Development
    Table 239. Key Raw Materials Lists
    Table 240. Raw Materials Key Suppliers Lists
    Table 241. Kidney Cancer Drugs Market Trends
    Table 242. Kidney Cancer Drugs Market Drivers
    Table 243. Kidney Cancer Drugs Market Challenges
    Table 244. Kidney Cancer Drugs Market Restraints
    Table 245. Kidney Cancer Drugs Distributors List
    Table 246. Kidney Cancer Drugs Downstream Customers
    Table 247. Research Programs/Design for This Report
    Table 248. Key Data Information from Secondary Sources
    Table 249. Key Data Information from Primary Sources
List of Figures
    Figure 1. Kidney Cancer Drugs Product Picture
    Figure 2. Global Kidney Cancer Drugs Market Size, 2018 VS 2022 VS 2029 (US$ Million)
    Figure 3. Global Kidney Cancer Drugs Market Size Status and Outlook (2018-2029) & (US$ Million)
    Figure 4. Global Kidney Cancer Drugs Sales Status and Outlook (2018-2029) & (K Units)
    Figure 5. Product Picture of Angiogenesis Inhibitors
    Figure 6. Global Angiogenesis Inhibitors Sales YoY Growth (2018-2029) & (K Units)
    Figure 7. Product Picture of mTOR Inhibitors
    Figure 8. Global mTOR Inhibitors Sales YoY Growth (2018-2029) & (K Units)
    Figure 9. Product Picture of Monoclonal Antibodies
    Figure 10. Global Monoclonal Antibodies Sales YoY Growth (2018-2029) & (K Units)
    Figure 11. Product Picture of Cytokine Immunotherapy (IL-2)
    Figure 12. Global Cytokine Immunotherapy (IL-2) Sales YoY Growth (2018-2029) & (K Units)
    Figure 13. Global Kidney Cancer Drugs Sales by Type (2018-2029) & (US$ Million)
    Figure 14. Global Kidney Cancer Drugs Sales Market Share by Type in 2022 & 2029
    Figure 15. North America Kidney Cancer Drugs Sales Market Share in Volume by Type in 2022
    Figure 16. North America Kidney Cancer Drugs Sales Market Share in Value by Type in 2022
    Figure 17. Europe Kidney Cancer Drugs Sales Market Share in Volume by Type in 2022
    Figure 18. Europe Kidney Cancer Drugs Sales Market Share in Value by Type in 2022
    Figure 19. Asia-Pacific Kidney Cancer Drugs Sales Market Share in Volume by Type in 2022
    Figure 20. Asia-Pacific Kidney Cancer Drugs Sales Market Share in Value by Type in 2022
    Figure 21. Latin America Kidney Cancer Drugs Sales Market Share in Volume by Type in 2022
    Figure 22. Latin America Kidney Cancer Drugs Sales Market Share in Value by Type in 2022
    Figure 23. Middle East and Africa Kidney Cancer Drugs Sales Market Share in Volume by Type in 2022
    Figure 24. Middle East and Africa Kidney Cancer Drugs Sales Market Share in Value by Type in 2022
    Figure 25. The 5 and 10 Largest Manufacturers in the World: Market Share by Kidney Cancer Drugs Sales in 2022
    Figure 26. The 5 and 10 Largest Manufacturers in the World: Market Share by Kidney Cancer Drugs Revenue in 2022
    Figure 27. Kidney Cancer Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2022
    Figure 28. Product Picture of Renal Cell Carcinoma (RCC)
    Figure 29. Global Renal Cell Carcinoma (RCC) Sales YoY Growth (2018-2029) & (K Units)
    Figure 30. Product Picture of Transitional Cell Carcinoma (TCC)
    Figure 31. Global Transitional Cell Carcinoma (TCC) Sales YoY Growth (2018-2029) & (K Units)
    Figure 32. Global Kidney Cancer Drugs Sales by Application (2018-2029) & (US$ Million)
    Figure 33. Global Kidney Cancer Drugs Sales Market Share by Application in 2022 & 2029
    Figure 34. North America Kidney Cancer Drugs Sales Market Share in Volume by Application in 2022
    Figure 35. North America Kidney Cancer Drugs Sales Market Share in Value by Application in 2022
    Figure 36. Europe Kidney Cancer Drugs Sales Market Share in Volume by Application in 2022
    Figure 37. Europe Kidney Cancer Drugs Sales Market Share in Value by Application in 2022
    Figure 38. Asia-Pacific Kidney Cancer Drugs Sales Market Share in Volume by Application in 2022
    Figure 39. Asia-Pacific Kidney Cancer Drugs Sales Market Share in Value by Application in 2022
    Figure 40. Latin America Kidney Cancer Drugs Sales Market Share in Volume by Application in 2022
    Figure 41. Latin America Kidney Cancer Drugs Sales Market Share in Value by Application in 2022
    Figure 42. Middle East and Africa Kidney Cancer Drugs Sales Market Share in Value by Application in 2022
    Figure 43. Key Raw Materials Price
    Figure 44. Kidney Cancer Drugs Manufacturing Cost Structure
    Figure 45. Kidney Cancer Drugs Industrial Chain Analysis
    Figure 46. Channels of Distribution
    Figure 47. Distributors Profiles
    Figure 48. Bottom-up and Top-down Approaches for This Report
    Figure 49. Data Triangulation
    Figure 50. Key Executives Interviewed

Kidney cancer, also known as renal cancer, is a type of cancer that starts in the cells in the kidney. The two most common types of kidney cancer are renal cell carcinoma (RCC) and transitional cell carcinoma (TCC) of the renal pelvis. These names reflect the type of cell from which the cancer developed. The different types of kidney cancer (such as RCC and TCC) develop in different ways, meaning that the diseases have different long term outcomes, and need to be staged and treated in different ways. RCC is responsible for approximately 80% of primary renal cancers, and TCC accounts the majority of the remainder.

Kidney Cancer Drugs report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Kidney Cancer Drugs market is projected to reach US$ 5501.9 million in 2029, increasing from US$ 3970.1 million in 2022, with the CAGR of 4.3% during the period of 2023 to 2029. Demand from Renal Cell Carcinoma (RCC) and Transitional Cell Carcinoma (TCC) are the major drivers for the industry.

Biological therapies are drugs which are used to kill cancer cells or stop them from growing. Biological therapies are used to try to shrink or control advanced kidney cancer and help people to live longer. You may be given biological therapies for kidney cancer that has already spread, or is at high-risk of coming back after surgery.

Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Kidney Cancer Drugs market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.

Manufacturers, Type, Application and Regions Listed in the Report:
By Company
    Bayer
    Roche
    GlaxoSmithKline
    Novartis
    Pfizer
    Abbott Laboratories
    Active Biotech
    Amgen
    Argos Therapeutics
    ArQule
    AVEO Pharmaceuticals
    Bionomics
    Bristol-Myers Squibb
    Cerulean Pharma
    Exelixis
    Genentech
    immatics biotechnologies
    Immunicum
    Ono Pharmaceutical
    Onyx Therapeutics
    Oxford BioMedica
    Prometheus Laboratories
    Seattle Genetics
    Taiwan Liposome
    Tracon Pharmaceuticals
    Wilex

Segment by Type
    Angiogenesis Inhibitors
    mTOR Inhibitors
    Monoclonal Antibodies
    Cytokine Immunotherapy (IL-2)

Segment by Application
    Renal Cell Carcinoma (RCC)
    Transitional Cell Carcinoma (TCC)

Segment by Region
    North America
        U.S.
        Canada
    Europe
        Germany
        France
        U.K.
        Italy
        Russia
    Asia-Pacific
        China
        Japan
        South Korea
        India
        Australia
        Taiwan
        Indonesia
        Thailand
        Malaysia
        Philippines
        Vietnam
    Latin America
        Mexico
        Brazil
        Argentina
    Middle East & Africa
        Turkey
        Saudi Arabia
        U.A.E

Each chapter of the report provides detailed information for readers to understand the Kidney Cancer Drugs market further:
Chapter 1: Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2023.
Chapter 2: Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Kidney Cancer Drugs, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Kidney Cancer Drugs industry.
Chapter 3: Historical (2018-2022) and forecast (2023-2029) volume and revenue analysis of Kidney Cancer Drugs in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4: Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2023.
Chapter 5 to 9: Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10: Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Kidney Cancer Drugs introduction, etc. Kidney Cancer Drugs Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11: Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12: Market Channel, Distributors and Customers are listed.
Chapter 13: QYResearch’s Conclusions of Kidney Cancer Drugs market based on comprehensive survey.
Chapter 14: Methodology and Data Sources adopted by QYResearch.